Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 3/20 | 0.41 |
| ▸ | C1S | P09871 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048668 | 0.89 | MEN1 (0.42) | PLAUC1SNPC1RAB9AMEN1 | |
| SCHEMBL4050951 | 0.87 | C1S (0.42) | KDM1AMAOAPOLBC1SNPC1 | |
| SCHEMBL4050006 | 0.81 | KDM1A (0.45) | KDM1AMAOAPOLBPLAUC1S | |
| SCHEMBL4050453 | 0.81 | ALDH1A1 (0.41) | NPC1RAB9AKMT2ALMNATP53 | |
| SCHEMBL4047040 | 0.78 | RAB9A (0.56) | POLBPLAUC1SNPC1RAB9A | |
| SCHEMBL4051453 | 0.77 | SMN1; SMN2 (0.62) | — | |
| SCHEMBL4050004 | 0.75 | RORC (0.48) | KDM1AMAOAPOLBPLAUC1S | |
| SCHEMBL4051276 | 0.72 | FBP1 (0.41) | RAB9AMEN1KMT2ALMNATP53 | |
| SCHEMBL4050602 | 0.70 | CASR (0.46) | POLBNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4048678 | 0.70 | PHGDH (0.46) | KDM1AMAOAPLAUC1SNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| EP-2029584-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | RB1, RBBP5, RRM2B | KDM1A 375/4885MAOA 3928/4885POLB 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.